Faculty Collaboration Database

CTSI Cores Search Research Informatics REDCap

Nirav N. Shah MD

Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Bone Marrow Transplant

Member of the Cancer Center
Member of the Center for Immunology

Send Message

Request Meeting

View Curriculum Vitae

Publications (149)

A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies (Kwiatek M, Murthy GSG, Hoffmann M, Tessoulin B, Danilov A, Alencar AJ, Shah NN, Ghesquieres H, Le Gouill S, Jurczak W, Han H, Yuen E, Patel V, Guo-Avrutin Y, Pauff JM, Roeker LE) Clinical Lymphoma Myeloma and Leukemia July 2025;25(7):512-519 SCOPUS ID: 2-s2.0-85218857552 07/01/2025

Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma. (Shah NN, Colina AS, Johnson BD, Szabo A, Furqan F, Kearl T, Schneider D, Vargas-Cortes M, Schmeling JL, Dwinell MB, Palen K, Longo W, Hematti P, Zamora AE, Hari P, Bucklan D, Cunningham A, Hamadani M, Fenske TS) J Clin Oncol 2025 Mar 31:JCO2402158 PMID: 40163793 03/31/2025

Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy. (Karmali R, Shouse G, Torka P, Moyo TK, Romancik J, Barta SK, Bhansali R, Cohen JB, Shah NN, Zurko J, Kenkre VP, Hess B, Stephens DM, Fitzgerald L, Ollila T, Tabiti B, Roy I, Ma S, Winter J, Pro B, Moreira J, Danilov AV, David K, Gordon LI, Epperla N) Blood Cancer J 2025 Mar 26;15(1):43 PMID: 40140360 PMCID: PMC11947441 SCOPUS ID: 2-s2.0-105000866957 03/27/2025

Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study. (Frigault MJ, Maziarz RT, Park JH, Lazaryan A, Shah NN, Svoboda J, Lekakis LJ, Reshef R, Phillips CL, Burke L, Lei J, Pratta M, Morariu-Zamfir R, DiPersio JF) Blood 2025 Mar 16 PMID: 40090005 SCOPUS ID: 2-s2.0-105008544409 03/16/2025 1 Citation

A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies. (Kwiatek M, Murthy GSG, Hoffmann M, Tessoulin B, Danilov A, Alencar AJ, Shah NN, Ghesquieres H, Le Gouill S, Jurczak W, Han H, Yuen E, Patel V, Guo-Avrutin Y, Pauff JM, Roeker LE) Clin Lymphoma Myeloma Leuk 2025 Jul;25(7):512-519 PMID: 40000354 SCOPUS ID: 2-s2.0-85218857552 02/26/2025

CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms. (Kearl TJ, Furqan F, Shah NN) Cancer Metastasis Rev 2024 Dec 01;44(1):12 PMID: 39617795 SCOPUS ID: 2-s2.0-85211169496 12/02/2024 2 Citations

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. (Shah NN, Wang M, Roeker LE, Patel K, Woyach JA, Wierda WG, Ujjani CS, Eyre TA, Zinzani PL, Alencar AJ, Ghia P, Lamanna N, Hoffmann MS, Patel MR, Flinn I, Gerson JN, Ma S, Coombs CC, Cheah CY, Lech-Maranda E, Fakhri B, Kim WS, Barve MA, Cohen JB, Jurczak W, Munir T, Thompson MC, Tsai DE, Bao K, Cangemi NA, Kherani JF, Walgren RA, Han H, Ruppert AS, Brown JR) Haematologica 2025 Jan 01;110(1):92-102 PMID: 39363864 PMCID: PMC11694105 SCOPUS ID: 2-s2.0-85214310390 10/04/2024 5 Citations

Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell Transplantation. (Akhtar OS, Arshad S, Lian Q, Ahn KW, D'Souza A, Dhakal B, Mohan M, Pasquini M, Longo W, Shah NN, Fenske TS, Hamadani M) Transplant Cell Ther 2024 Dec;30(12):1191.e1-1191.e8 PMID: 39303985 SCOPUS ID: 2-s2.0-85206435293 09/21/2024

Point-of-care CAR T manufacturing solutions: can 1 model fit all? (Urbano-Ispizua Á, Shah NN, Kekre N) Blood Adv 2024 Dec 10;8(23):6133-6136 PMID: 39265170 PMCID: PMC11707413 SCOPUS ID: 2-s2.0-85212238560 09/12/2024 4 Citations

Knowledge, skills, and confidence gaps impacting treatment decision making in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma: a quantitative survey study in France, Germany, and the United States. (Peloquin S, Cymbalista F, Dreyling M, Shah NN, Murray S, Del Fiacco R, Muehlenbein CE, Lazure P) BMC Cancer 2024 Aug 13;24(1):1003 PMID: 39138575 PMCID: PMC11321192 SCOPUS ID: 2-s2.0-85201250614 08/14/2024

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. (Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, Lamanna N, Ma S, Jagadeesh D, Munir T, Wang Y, Eyre TA, Rhodes JM, McKinney M, Lech-Maranda E, Tam CS, Jurczak W, Izutsu K, Alencar AJ, Patel MR, Seymour JF, Woyach JA, Thompson PA, Abada PB, Ho C, McNeely SC, Marella N, Nguyen B, Wang C, Ruppert AS, Nair B, Liu H, Tsai DE, Roeker LE, Ghia P) Lancet Haematol 2024 Sep;11(9):e682-e692 PMID: 39033770 SCOPUS ID: 2-s2.0-85200244218 07/22/2024 11 Citations

Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission. (Shadman M, Ahn KW, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, Ahmed N, Hill B, Hossain NM, Riedell P, Gopal AK, Grover N, Frigault M, Brammer J, Ghosh N, Merryman R, Lazaryan A, Ram R, Hertzberg M, Savani B, Awan F, Khimani F, Ahmed S, Kenkre VP, Ulrickson M, Shah N, Kharfan-Dabaja MA, Herrera A, Sauter C, Hamadani M) Blood Cancer J 2024 Jul 08;14(1):108 PMID: 38977682 PMCID: PMC11231252 SCOPUS ID: 2-s2.0-85197736867 07/09/2024 7 Citations

Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. (Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, Akhtar O, D'Souza A, Pasquini M, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Shah NN, Hamadani M) Blood Adv 2024 Aug 27;8(16):4320-4329 PMID: 38889435 PMCID: PMC11372811 SCOPUS ID: 2-s2.0-85203009004 06/18/2024 8 Citations

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. (Roeker LE, Woyach JA, Cheah CY, Coombs CC, Shah NN, Wierda WG, Patel MR, Lamanna N, Tsai DE, Nair B, Wang C, Zhao X, Liu D, Radtke D, Chapman S, Marella N, McNeely SC, Brown JR) Blood 2024 Sep 26;144(13):1374-1386 PMID: 38861666 PMCID: PMC11451378 SCOPUS ID: 2-s2.0-85198077615 06/11/2024 8 Citations

Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies. (Roeker LE, Coombs CC, Shah NN, Jurczak W, Woyach JA, Cheah CY, Patel K, Maddocks K, Wang Y, Zinzani PL, Munir T, Koh Y, Thompson MC, Muehlenbein CE, Wang C, Sizelove R, Abhyankar S, Hasanabba S, Tsai DE, Eyre TA, Wang M) Acta Haematol 2025;148(2):180-197 PMID: 38824917 PMCID: PMC11617602 SCOPUS ID: 2-s2.0-105002058793 06/03/2024

Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion. (Watt KD, Rolak S, Foley DP, Plichta JK, Pruthi S, Farr D, Zwald FO, Carvajal RD, Dudek AZ, Sanger CB, Rocco R, Chang GJ, Dizon DS, Langstraat CL, Teoh D, Agarwal PK, Al-Qaoud T, Eggener S, Kennedy CC, D'Cunha J, Mohindra NA, Stewart S, Habermann TH, Schuster S, Lunning M, Shah NN, Gertz MA, Mehta J, Suvannasankha A, Verna E, Farr M, Blosser CD, Hammel L, Al-Adra DP) Transplantation 2024 Dec 01;108(12):2336-2350 PMID: 38771067 SCOPUS ID: 2-s2.0-85207752060 05/21/2024 2 Citations

The role of noncovalent BTK inhibitors in the era of covalent BTK inhibitors. (Furqan F, Shah NN) Clin Adv Hematol Oncol 2024 Apr;22(3):140-147 PMID: 38588273 SCOPUS ID: 2-s2.0-85190320304 04/08/2024

Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy. (Karmali R, Machhi R, Epperla N, Shouse G, Romancik J, Moyo TK, Kenkre V, Ollila TA, Fitzgerald L, Hess B, David K, Roy I, Zurko J, Chowdhury SM, Annunzio K, Ferdman R, Bhansali RS, Harris EI, Liu J, Nizamuddin I, Ma S, Moreira J, Winter J, Pro B, Stephens DM, Danilov A, Shah NN, Cohen JB, Barta SK, Torka P, Gordon LI) Blood Adv 2024 May 28;8(10):2592-2599 PMID: 38531057 PMCID: PMC11145749 SCOPUS ID: 2-s2.0-85195045599 03/26/2024 11 Citations

Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy. (Melody M, Epperla N, Shouse G, Romancik J, Allen P, Moyo TK, Kenkre V, Ollila T, Fitzgerald L, Hess B, David K, Herr MM, Odetola O, Lin A, Moreira J, Ma S, Winter JN, Roy I, Stephens D, Danilov A, Shah NN, Barta SK, Cortese M, Cohen JB, Gordon LI, Karmali R) Blood Adv 2024 May 28;8(10):2327-2331 PMID: 38498727 PMCID: PMC11126789 SCOPUS ID: 2-s2.0-85195043883 03/19/2024 11 Citations

Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. (Mohan M, Szabo A, Patwari A, Esselmann J, Patel T, Bachu R, Rein LE, Janardan A, Bhatlapenumarthi V, Annyapu E, Skoog C, Goff A, Hadidi SA, Radhakrishnan SV, Thanendrarajan S, Zangari M, Shah N, van Rhee F, Dhakal B, Hamadani M, D'Souza A, Schinke C) Bone Marrow Transplant 2024 May;59(5):647-652 PMID: 38361116 SCOPUS ID: 2-s2.0-85185115608 02/16/2024 9 Citations

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. (Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil L, Thieblemont C, Ursu R, Bartlett N, Nachar V, Weiss J, Osterson J, Patel K, Brody J, Abramson JS, Lunning M, Shah NN, Ayed A, Kamdar M, Parsons B, Caimi P, Flinn I, Herrera A, Sharman J, McKenna M, Armand P, Kahl B, Smith S, Zelenetz A, Budde LE, Hutchings M, Phillips T, Dickinson M) Blood 2024 Apr 18;143(16):1565-1575 PMID: 38252906 SCOPUS ID: 2-s2.0-85186599726 01/22/2024 60 Citations

A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen. (Karmali R, Galvez C, Hamadani M, Gordon L, Winter J, Ma S, Nelson V, Fenske TS, Shah NN, Jagadeesh D, Klein A, Helenowski I, Chen R, Mi X, Petrich A, Evens AM, Pro B) Blood Adv 2024 Apr 09;8(7):1612-1620 PMID: 38237077 PMCID: PMC10987893 SCOPUS ID: 2-s2.0-85190159731 01/18/2024 1 Citation

Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma. (Rezazadeh A, Pruett J, Detzner A, Edwin N, Hamadani M, Shah NN, Fenske TS) Clin Lymphoma Myeloma Leuk 2024 Apr;24(4):254-259 PMID: 38195321 SCOPUS ID: 2-s2.0-85181916717 01/10/2024 3 Citations

Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation. (Chhabra S, Jerkins JH, Monahan K, Szabo A, Shah NN, Abedin S, Runaas L, Fenske TS, Pasquini MC, Shaw BE, Drobyski WR, Saber W, D'Souza A, Dhakal B, Mohan M, Longo W, Hamadani M) Bone Marrow Transplant 2024 Mar;59(3):373-379 PMID: 38177221 SCOPUS ID: 2-s2.0-85181508004 01/05/2024 3 Citations

Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis. (Abid MB, Rubin M, Szabo A, Longo W, Fenske TS, McCoy C, Lorge A, Abedin S, D'Souza A, Dhakal B, Shah NN, Hamadani M) Transplant Cell Ther 2024 Mar;30(3):285-297 PMID: 38142942 SCOPUS ID: 2-s2.0-85183537164 12/25/2023 9 Citations

Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation. (Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M, Chhabra S, Radhakrishnan S, Mohan M, Narra R, Dong J, Janz S, Shah NN, Hamadani M, D'Souza A, Hari P, Dhakal B) Br J Haematol 2024 Mar;204(3):887-891 PMID: 38054558 SCOPUS ID: 2-s2.0-85178904872 12/06/2023 3 Citations

Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study (Epperla N, Feng L, Shah NN, Fitzgerald L, Shah H, Stephens DM, Lee CJ, Ollila T, Shouse G, Danilov AV, David KA, Torka P, Hashmi H, Hess B, Barta SK, Romancik JT, Cohen JB, Annunzio K, Kittai AS, Reneau J, Zurko J, Nizamuddin IA, Winter JN, Gordon LI, Ma S, Patel R, Nastoupil L, Ahmed S, Karmali R) Journal of Hematology and Oncology December 2023;16(1) SCOPUS ID: 2-s2.0-85176094636 12/01/2023 26 Citations

Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. (Epperla N, Feng L, Shah NN, Fitzgerald L, Shah H, Stephens DM, Lee CJ, Ollila T, Shouse G, Danilov AV, David KA, Torka P, Hashmi H, Hess B, Barta SK, Romancik JT, Cohen JB, Annunzio K, Kittai AS, Reneau J, Zurko J, Nizamuddin IA, Winter JN, Gordon LI, Ma S, Patel R, Nastoupil L, Ahmed S, Karmali R) J Hematol Oncol 2023 Nov 09;16(1):111 PMID: 37946255 PMCID: PMC10633964 SCOPUS ID: 2-s2.0-85176094636 11/10/2023 26 Citations

Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt's Lymphoma. (Kenkel TJ, Sridhar N, Hammons LR, Hintzke M, Shah NN) Med Sci (Basel) 2023 Oct 12;11(4) PMID: 37873752 PMCID: PMC10594436 SCOPUS ID: 2-s2.0-85175356501 10/24/2023 1 Citation

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. (Bowers JT, Anna J, Bair SM, Annunzio K, Epperla N, Pullukkara JJ, Gaballa S, Spinner MA, Li S, Messmer MR, Nguyen J, Ayers EC, Wagner CB, Hu B, Di M, Huntington SF, Furqan F, Shah NN, Chen C, Ballard HJ, Hughes ME, Chong EA, Nasta SD, Barta SK, Landsburg DJ, Svoboda J) Blood Adv 2023 Nov 14;7(21):6630-6638 PMID: 37595053 PMCID: PMC10628810 SCOPUS ID: 2-s2.0-85177236811 08/18/2023 7 Citations

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. (Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, Munir T, Lech-Maranda E, Lamanna N, Tam CS, Shah NN, Coombs CC, Ujjani CS, Fakhri B, Cheah CY, Patel MR, Alencar AJ, Cohen JB, Gerson JN, Flinn IW, Ma S, Jagadeesh D, Rhodes JM, Hernandez-Ilizaliturri F, Zinzani PL, Seymour JF, Balbas M, Nair B, Abada P, Wang C, Ruppert AS, Wang D, Tsai DE, Wierda WG, Jurczak W) N Engl J Med 2023 Jul 06;389(1):33-44 PMID: 37407001 SCOPUS ID: 2-s2.0-85165276486 07/06/2023 23 Citations

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. (Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG) Lancet 2023 Aug 19;402(10402):641-654 PMID: 37295445 PMCID: PMC11753452 SCOPUS ID: 2-s2.0-85163400261 06/10/2023 100 Citations

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023. (Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon S, Ou S, Papp E, Chen Y, Wierda W) Hematol Oncol 2023 Jun;41 Suppl 2:60-62 PMID: 39112401 SCOPUS ID: 2-s2.0-85200939306 06/01/2023

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development. (Dickinson MJ, Barba P, Jäger U, Shah NN, Blaise D, Briones J, Shune L, Boissel N, Bondanza A, Mariconti L, Marchal AL, Quinn DS, Yang J, Price A, Sohoni A, Treanor LM, Orlando EJ, Mataraza J, Davis J, Lu D, Zhu X, Engels B, Moutouh-de Parseval L, Brogdon JL, Moschetta M, Flinn IW) Cancer Discov 2023 Sep 06;13(9):1982-1997 PMID: 37249512 PMCID: PMC10481129 SCOPUS ID: 2-s2.0-85169848226 05/30/2023 81 Citations

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. (Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, Koh Y, Izutsu K, Gerson JN, Flinn I, Tessoulin B, Alencar AJ, Ma S, Lewis D, Lech-Maranda E, Rhodes J, Patel K, Maddocks K, Lamanna N, Wang Y, Tam CS, Munir T, Nagai H, Hernandez-Ilizaliturri F, Kumar A, Fenske TS, Seymour JF, Zelenetz AD, Nair B, Tsai DE, Balbas M, Walgren RA, Abada P, Wang C, Zhao J, Mato AR, Shah NN) J Clin Oncol 2023 Aug 20;41(24):3988-3997 PMID: 37192437 PMCID: PMC10461952 SCOPUS ID: 2-s2.0-85166977934 05/16/2023 58 Citations

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. (Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN) Transplant Cell Ther 2023 Jul;29(7):438.e1-438.e16 PMID: 36906275 PMCID: PMC10330221 SCOPUS ID: 2-s2.0-85152271344 03/12/2023 174 Citations

Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial. (Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J) Transplant Cell Ther 2023 Mar;29(3):208.e1-208.e6 PMID: 36584941 PMCID: PMC9992261 SCOPUS ID: 2-s2.0-85146784394 12/31/2022 36 Citations

Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells. (Sasu BJ, Opiteck GJ, Gopalakrishnan S, Kaimal V, Furmanak T, Huang D, Goswami A, He Y, Chen J, Nguyen A, Balakumaran A, Shah NN, Hamadani M, Bone KM, Prashad S, Bowen MA, Pertel T, Embree HD, Gidwani SG, Chang D, Moore A, Leonard M, Amado RG) Mol Ther 2023 Mar 01;31(3):676-685 PMID: 36518079 PMCID: PMC10014221 SCOPUS ID: 2-s2.0-85145741279 12/16/2022 19 Citations

Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy. (Furqan F, Maring M, Szabo A, Fenske TS, Hamadani M, Shah NN) Blood Adv 2023 Jun 13;7(11):2463-2467 PMID: 36417762 PMCID: PMC10241849 SCOPUS ID: 2-s2.0-85179466193 11/24/2022 3 Citations

BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma. (Eyre TA, Shah NN, Dreyling M, Jurczak W, Wang Y, Cheah CY, Song Y, Gandhi M, Chay C, Sharman J, Andorsky DJ, Messersmith HM, Ruppert AS, Muthig VA, Ito R, Wang ML) Future Oncol 2022 Nov;18(36):3961-3969 PMID: 36377973 SCOPUS ID: 2-s2.0-85148113726 11/16/2022 14 Citations

Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss. (Furqan F, Shah NN) Annu Rev Med 2023 Jan 27;74:279-291 PMID: 36332638 SCOPUS ID: 2-s2.0-85147091798 11/05/2022 18 Citations

Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885]. (Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M) Transplant Cell Ther 2022 Oct;28(10):717 PMID: 36202527 SCOPUS ID: 2-s2.0-85101258094 10/07/2022

Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes. (Knight JM, Hackett E, Szabo A, Wu R, Sauber G, Johnson B, Cusatis RN, Aughey E, Cole SW, Hillard CJ, Shah NN) Haematologica 2023 Feb 01;108(2):588-593 PMID: 36200427 PMCID: PMC9890001 SCOPUS ID: 2-s2.0-85147234722 10/07/2022 1 Citation

Corrigendum to ‘Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation’ [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885, (S1083879120304146), (10.1016/j.bbmt.2020.07.005)] (Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M) Transplantation and Cellular Therapy October 2022;28(10):717 SCOPUS ID: 2-s2.0-85101258094 10/01/2022

CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study (Coombs CC, Pagel JM, Shah NN, Lamanna N, Munir T, Lech-Maranda E, Eyre TA, Woyach JA, Wierda WG, Cheah CY, Cohen JB, Roeker LE, Patel MR, Fakhri B, Barve MA, Tam CS, Lewis D, Gerson JN, Alencar A, Ujjani C, Flinn I, Sundaram S, Ma S, Jagadeesh D, Rhodes J, Taylor J, Abdel-Wahab O, Ghia P, Schuster SJ, Wang D, Nair B, Zhu E, Tsai DE, Davids MS, Brown JR, Jurczak W, Mato AR) Clinical Lymphoma Myeloma and Leukemia October 2022;22:S268-S269 SCOPUS ID: 2-s2.0-85138202994 10/01/2022 2 Citations

MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress) (Ito R, Eyre TA, Shah NN, Gouill SL, Dreyling M, Vandenberghe E, Jurczak W, Wang Y, Cheah CY, Gandhi M, Chay C, Sharman J, Andorsky DJ, Song Y, Stark A, Muthig V, Wang ML) Clinical Lymphoma Myeloma and Leukemia October 2022;22:S395-S396 SCOPUS ID: 2-s2.0-85138193966 10/01/2022 5 Citations

MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study (Cohen JB, Shah NN, Alencar AJ, Gerson JN, Patel MR, Fakhri B, Jurczak W, Tan XN, Lewis KL, Fenske T, Coombs CC, Flinn IW, Lewis DJ, Gouill SL, Palomba ML, Woyach JA, Pagel JM, Lamanna N, Barve MA, Ghia P, Eyre TA, Zinzani PL, Ujjani CS, Koh Y, Izutsu K, Lech-Maranda E, Tam CS, Sundaram S, Yin M, Nair B, Tsai DE, Balbas M, Mato AR, Cheah CY, Wang ML) Clinical Lymphoma Myeloma and Leukemia October 2022;22:S394-S395 SCOPUS ID: 2-s2.0-85138145548 10/01/2022 14 Citations

MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress). (Ito R, Eyre TA, Shah NN, Gouill SL, Dreyling M, Vandenberghe E, Jurczak W, Wang Y, Cheah CY, Gandhi M, Chay C, Sharman J, Andorsky DJ, Song Y, Stark A, Muthig V, Wang ML) Clin Lymphoma Myeloma Leuk 2022 Oct;22 Suppl 2:S395-S396 PMID: 36164121 SCOPUS ID: 2-s2.0-85138193966 09/28/2022 5 Citations

MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study. (Cohen JB, Shah NN, Alencar AJ, Gerson JN, Patel MR, Fakhri B, Jurczak W, Tan XN, Lewis KL, Fenske T, Coombs CC, Flinn IW, Lewis DJ, Gouill SL, Palomba ML, Woyach JA, Pagel JM, Lamanna N, Barve MA, Ghia P, Eyre TA, Zinzani PL, Ujjani CS, Koh Y, Izutsu K, Lech-Maranda E, Tam CS, Sundaram S, Yin M, Nair B, Tsai DE, Balbas M, Mato AR, Cheah CY, Wang ML) Clin Lymphoma Myeloma Leuk 2022 Oct;22 Suppl 2:S394-S395 PMID: 36164120 SCOPUS ID: 2-s2.0-85138145548 09/28/2022 14 Citations

Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination. (Chhabra S, Szabo A, Clurman A, McShane K, Waters N, Eastwood D, Samanas L, Fei T, Armijo G, Abedin S, Longo W, Hari P, Hamadani M, Shah NN, Runaas L, Jerkins JH, Van den Brink M, Peled JU, Drobyski WR) Haematologica 2023 Jan 01;108(1):250-256 PMID: 36106394 PMCID: PMC9827178 SCOPUS ID: 2-s2.0-85145424654 09/16/2022 7 Citations

Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL. (Zurko J, Nizamuddin I, Epperla N, David K, Cohen JB, Moyo TK, Ollila T, Hess B, Roy I, Ferdman R, Liu J, Chowdhury SM, Romancik J, Bhansali RS, Harris EI, Sorrell M, Masel R, Kittai AS, Denlinger N, Sigmund AM, Fitzgerald L, Galvez C, Ma S, Winter J, Pro B, Gordon LI, Danilov A, Stephens D, Shah NN, Kenkre V, Barta SK, Torka P, Shouse G, Karmali R) Blood Adv 2023 Jun 27;7(12):2657-2669 PMID: 36094847 PMCID: PMC10333741 SCOPUS ID: 2-s2.0-85164974665 09/13/2022 27 Citations

Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells. (Zurko JC, Fenske TS, Johnson BD, Bucklan D, Szabo A, Xu H, Chaney K, Hamadani M, Hari P, Shah NN) Am J Hematol 2022 Dec;97(12):1580-1588 PMID: 36068950 SCOPUS ID: 2-s2.0-85138335080 09/08/2022 18 Citations

Perspective: An International Fludarabine Shortage: Supply Chain Issues Impacting Transplantation and Immune Effector Cell Therapy Delivery. (Maziarz RT, Diaz A, Miklos DB, Shah NN) Transplant Cell Ther 2022 Nov;28(11):723-726 PMID: 35940526 SCOPUS ID: 2-s2.0-85137718544 08/09/2022 23 Citations

Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. (Ahmed G, Bhasin-Chhabra B, Szabo A, Shah NN, Longo W, Dhakal B, Chhabra S, D'Souza A, Fenske TS, Hamadani M) Clin Lymphoma Myeloma Leuk 2022 Nov;22(11):863-868 PMID: 35934632 SCOPUS ID: 2-s2.0-85135507182 08/08/2022 9 Citations

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. (Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF) Haematologica 2023 Jan 01;108(1):98-109 PMID: 35833303 PMCID: PMC9827150 SCOPUS ID: 2-s2.0-85144275501 07/15/2022 54 Citations

Bispecific CAR T-cells for B-cell Malignancies. (Furqan F, Shah NN) Expert Opin Biol Ther 2022 Aug;22(8):1005-1015 PMID: 35653589 SCOPUS ID: 2-s2.0-85131517167 06/03/2022 16 Citations

Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy. (Knight JM, Szabo A, Arapi I, Wu R, Emmrich A, Hackett E, Sauber G, Yim S, Johnson B, Hari P, Schneider D, Dropulic B, Cusatis RN, Cole SW, Hillard CJ, Shah NN) Commun Med (Lond) 2022;2(1):49 PMID: 35603278 PMCID: PMC9098435 SCOPUS ID: 2-s2.0-85134214336 05/24/2022 12 Citations

Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies. (Zurko JC, Xu H, Chaney K, Schneider D, Szabo A, Hari P, Johnson BD, Shah NN) Cytotherapy 2022 Aug;24(8):767-773 PMID: 35597752 SCOPUS ID: 2-s2.0-85130432792 05/22/2022 12 Citations

Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol. (Johnson AK, Lorimer EL, Szabo A, Wu R, Shah NN, D'Souza A, Chhabra S, Hamadani M, Dhakal B, Hari P, Rao S, Carlson K, Williams CL, Knight JM) Yale J Biol Med 2022 Mar;95(1):45-56 PMID: 35370486 PMCID: PMC8961707 SCOPUS ID: 2-s2.0-85127524780 04/05/2022 5 Citations

Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome. (Zurko JC, Johnson BD, Aschenbrenner E, Fenske TS, Hamadani M, Hari P, Shah NN) JAMA Oncol 2022 May 01;8(5):773-775 PMID: 35266965 PMCID: PMC8914887 SCOPUS ID: 2-s2.0-85126591538 03/11/2022 23 Citations

Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. (Abid MB, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M, Shah NN, Fenske TS, Abedin S, Runaas L, D'Souza A, Chhabra S, Dhakal B, Hamadani M) Cancer Cell 2022 Apr 11;40(4):340-342 PMID: 35202585 PMCID: PMC8864440 SCOPUS ID: 2-s2.0-85127542763 02/25/2022 40 Citations

Hemophagocytosis in cerebrospinal fluid after CAR T-cell therapy. (Shah NN, Harrington AM) Blood 2022 Feb 17;139(7):1116 PMID: 35175320 SCOPUS ID: 2-s2.0-85124777621 02/18/2022 4 Citations

Mimicking Myelodysplastic Syndrome: Importance of Differential Diagnosis. (Luo T, Zurko J, Astle J, Shah NN) Case Rep Hematol 2021;2021:9661765 PMID: 34881068 PMCID: PMC8648467 12/10/2021

CAR T-cell therapy for secondary CNS DLBCL. (Ahmed G, Hamadani M, Shah NN) Blood Adv 2021 Dec 28;5(24):5626-5630 PMID: 34551065 PMCID: PMC8714710 SCOPUS ID: 2-s2.0-85122300713 09/23/2021 52 Citations

Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model? (Palen K, Zurko J, Johnson BD, Hari P, Shah NN) Cytotherapy 2021 Nov;23(11):985-990 PMID: 34538575 SCOPUS ID: 2-s2.0-85115015094 09/21/2021 16 Citations

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. (Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, Ramakrishnan A, DeFilipp Z, Salhotra A, Chai-Ho W, Mehta R, Wang T, Arora M, Pusic I, Saad A, Shah NN, Abhyankar S, Bachier C, Galvin J, Im A, Langston A, Liesveld J, Juckett M, Logan A, Schachter L, Alavi A, Howard D, Waksal HW, Ryan J, Eiznhamer D, Aggarwal SK, Ieyoub J, Schueller O, Green L, Yang Z, Krenz H, Jagasia M, Blazar BR, Pavletic S) Blood 2021 Dec 02;138(22):2278-2289 PMID: 34265047 PMCID: PMC8641099 SCOPUS ID: 2-s2.0-85118485903 07/16/2021 199 Citations

Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. (Dhakal B, Thapa B, Dong H, Tarima S, Chhabra S, D'Souza A, Drobyski W, Abid M, Shah N, Fenske T, Longo W, Hari P, Hamadani M) Clin Lymphoma Myeloma Leuk 2021 Oct;21(10):e775-e781 PMID: 34257042 SCOPUS ID: 2-s2.0-85110347842 07/15/2021 3 Citations

Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. (Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS) JAMA Oncol 2021 Jul 01;7(7):993-1003 PMID: 33956047 PMCID: PMC8283558 SCOPUS ID: 2-s2.0-85105866863 05/07/2021 58 Citations

Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. (Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M) Blood Cancer J 2021 Apr 29;11(4):82 PMID: 33927193 PMCID: PMC8085088 SCOPUS ID: 2-s2.0-85105142269 05/01/2021

National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. (Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J) J Clin Oncol 2021 Jun 20;39(18):1971-1982 PMID: 33905264 PMCID: PMC8260905 SCOPUS ID: 2-s2.0-85108386444 04/28/2021 144 Citations

PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response. (Zurko J, Chaney K, Astle JM, Johnson BD, Hari P, Shah NN) Haematologica 2021 Oct 01;106(10):2788-2790 PMID: 33853295 PMCID: PMC8485669 SCOPUS ID: 2-s2.0-85116219490 04/16/2021 4 Citations

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. (Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M) Lancet 2021 Mar 06;397(10277):892-901 PMID: 33676628 PMCID: PMC11758240 SCOPUS ID: 2-s2.0-85101887008 03/08/2021 358 Citations

Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma? (Shah NN, Hamadani M) J Clin Oncol 2021 Feb 10;39(5):487-498 PMID: 33434076 SCOPUS ID: 2-s2.0-85102044262 01/13/2021 27 Citations

Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? (Shah NN, Ahn KW, Litovich C, He Y, Sauter C, Fenske TS, Hamadani M) Blood 2021 Mar 11;137(10):1416-1423 PMID: 33120429 PMCID: PMC7955408 SCOPUS ID: 2-s2.0-85102604135 10/30/2020 61 Citations

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. (Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P) Nat Med 2020 Oct;26(10):1569-1575 PMID: 33020647 SCOPUS ID: 2-s2.0-85092105030 10/07/2020 352 Citations

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. (Cuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Schuster SJ, Shah NN, Ujjani CS, Roeker L, Orlandi EM, Billio A, Trentin L, Spacek M, Marchetti M, Tedeschi A, Ilariucci F, Gaidano G, Doubek M, Farina L, Molica S, Di Raimondo F, Coscia M, Mauro FR, de la Serna J, Medina Perez A, Ferrarini I, Cimino G, Cavallari M, Cucci R, Vignetti M, Foà R, Ghia P, GIMEMA, European Research Initiative (ERIC) on CLL, US study group) Cancer Med 2020 Nov;9(22):8468-8479 PMID: 32969597 PMCID: PMC7666748 SCOPUS ID: 2-s2.0-85091352623 09/25/2020 13 Citations

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy. (Ujjani C, Mato A, Hill BT, Allan JN, Lansigan F, Jacobs R, Skarbnik A, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M) Blood Lymphat Cancer 2020;10:1-5 PMID: 32943973 PMCID: PMC7473982 09/19/2020

Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma. (Cronk RJ, Zurko J, Shah NN) Cancers (Basel) 2020 Sep 05;12(9) PMID: 32899464 PMCID: PMC7564024 SCOPUS ID: 2-s2.0-85090236837 09/10/2020 41 Citations

Bispecific chimeric antigen receptor T cell therapy for b cell malignancies and multiple myeloma (Cronk RJ, Zurko J, Shah NN) Cancers September 2020;12(9):1-15 SCOPUS ID: 2-s2.0-85090236837 09/01/2020 41 Citations

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. (Roeker LE, Dreger P, Brown JR, Lahoud OB, Eyre TA, Brander DM, Skarbnik A, Coombs CC, Kim HT, Davids M, Manchini ST, George G, Shah N, Voorhees TJ, Orchard KH, Walter HS, Arumainathan AK, Sitlinger A, Park JH, Geyer MB, Zelenetz AD, Sauter CS, Giralt SA, Perales MA, Mato AR) Blood Adv 2020 Aug 25;4(16):3977-3989 PMID: 32841336 PMCID: PMC7448605 SCOPUS ID: 2-s2.0-85090336061 08/26/2020 68 Citations

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. (Nazha A, Hu ZH, Wang T, Lindsley RC, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn JY, Cerny J, Copelan E, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla SM, Gale RP, George B, Gergis U, Grunwald MR, Hamilton B, Hashmi S, Hildebrandt GC, Inamoto Y, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Liesveld JL, Litzow MR, Majhail NS, Murthy HS, Nathan S, Nishihori T, Pawarode A, Rizzieri D, Sabloff M, Savani BN, Schachter L, Schouten HC, Seo S, Shah NN, Solh M, Valcárcel D, Vij R, Warlick E, Wirk B, Wood WA, Yared JA, Alyea E, Popat U, Sobecks RM, Scott BL, Nakamura R, Saber W) Biol Blood Marrow Transplant 2020 Nov;26(11):2139-2146 PMID: 32781289 PMCID: PMC7609542 SCOPUS ID: 2-s2.0-85090061841 08/12/2020 16 Citations

Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. (Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W) Blood Adv 2020 Jul 14;4(13):3180-3190 PMID: 32663298 PMCID: PMC7362362 SCOPUS ID: 2-s2.0-85088320644 07/15/2020 21 Citations

Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. (Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2020 Oct;26(10):1876-1885 PMID: 32653622 PMCID: PMC7571859 SCOPUS ID: 2-s2.0-85089134303 07/13/2020 6 Citations

Treatment-Emergent Tumor Lysis Syndrome With PI3Kδ-γ Inhibition After CAR T-Cell Therapy for Chronic Lymphocytic Leukemia. (Shah NN, Jerkins JH, Johnson BD, Hari P) JCO Oncol Pract 2020 Sep;16(9):613-614 PMID: 32603254 SCOPUS ID: 2-s2.0-85090870606 07/01/2020 2 Citations

Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. (Abid MB, Hamadani M, Szabo A, Hari PN, Graham MB, Frank MO, Collier WS, Abedin S, Jerkins JH, Pasquini MC, Runaas L, Shah NN, Chhabra S) Biol Blood Marrow Transplant 2020 Sep;26(9):1670-1678 PMID: 32562858 SCOPUS ID: 2-s2.0-85087739042 06/21/2020 19 Citations

Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome. (Shah NN, Johnson BD, Fenske TS, Raj RV, Hari P) Blood Adv 2020 May 26;4(10):2119-2122 PMID: 32407473 PMCID: PMC7252557 SCOPUS ID: 2-s2.0-85086848668 05/15/2020 43 Citations

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. (Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, Fazal S, Dawkins FW, Arbushites MC, Tian C, Connelly-Smith L, Howell MD, Khoury HJ) Blood 2020 May 14;135(20):1739-1749 PMID: 32160294 PMCID: PMC7229262 SCOPUS ID: 2-s2.0-85083637011 03/12/2020 220 Citations

Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. (Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW) Blood Adv 2020 Feb 11;4(3):467-476 PMID: 32027744 PMCID: PMC7013267 SCOPUS ID: 2-s2.0-85082178004 02/07/2020 42 Citations

Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. (Badar T, Shah NN) Curr Treat Options Oncol 2020 Feb 05;21(2):16 PMID: 32025828 SCOPUS ID: 2-s2.0-85079049524 02/07/2020 23 Citations

Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. (Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN) Biol Blood Marrow Transplant 2020 May;26(5):893-901 PMID: 31982543 SCOPUS ID: 2-s2.0-85080146585 01/27/2020 16 Citations

Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. (Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, Saini N, Shah AR, Patel RD, Ahmed S, Shah NN, Cashen AF, Hamadani M, Fenske TS) Blood Adv 2020 Jan 14;4(1):47-54 PMID: 31899797 PMCID: PMC6960457 SCOPUS ID: 2-s2.0-85078133666 01/04/2020 22 Citations

Gut microbiome and CAR-T therapy. (Abid MB, Shah NN, Maatman TC, Hari PN) Exp Hematol Oncol 2019;8:31 PMID: 31827982 PMCID: PMC6862813 SCOPUS ID: 2-s2.0-85075584597 12/13/2019 40 Citations

Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. (Chen YB, Shah NN, Renteria AS, Cutler C, Jansson J, Akbari M, Chen C, Quadri S, Parfionovas A, Devine SM) Blood Adv 2019 Dec 10;3(23):4136-4146 PMID: 31821456 PMCID: PMC6963235 SCOPUS ID: 2-s2.0-85083376318 12/11/2019 39 Citations

Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. (Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL) J Clin Oncol 2020 Feb 10;38(5):415-422 PMID: 31815579 PMCID: PMC8312030 SCOPUS ID: 2-s2.0-85079075868 12/10/2019 203 Citations

Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. (Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M) Blood Cancer J 2019 Dec 03;9(12):97 PMID: 31796726 PMCID: PMC6890709 SCOPUS ID: 2-s2.0-85075936084 12/05/2019 12 Citations

Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease. (Chhabra S, Jerkins JH, Conto JE, Zellner K, Shah NN, Hari PN, Hamadani M) Leuk Lymphoma 2020 Apr;61(4):869-874 PMID: 31762357 SCOPUS ID: 2-s2.0-85075533403 11/26/2019 20 Citations

Gut microbiome and CAR-T therapy (Abid MB, Shah NN, Maatman TC, Hari PN) Experimental Hematology and Oncology 19 November 2019;8(1) SCOPUS ID: 2-s2.0-85075584597 11/19/2019 40 Citations

Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. (Solomon SR, St Martin A, Shah NN, Fatobene G, Al Malki MM, Ballen KK, Bashey A, Bejanyan N, Bolaños Meade J, Brunstein CG, DeFilipp Z, Champlin RE, Fuchs EJ, Hamadani M, Hematti P, Kanakry CG, McGuirk JP, McNiece IK, Ciurea SO, Pasquini MC, Rocha V, Romee R, Patel SS, Vasu S, Waller EK, Wingard JR, Zhang MJ, Eapen M) Blood Adv 2019 Oct 08;3(19):2836-2844 PMID: 31582392 PMCID: PMC6784523 SCOPUS ID: 2-s2.0-85073446898 10/05/2019 44 Citations

Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database. (Guru Murthy GS, Szabo A, Hamadani M, Fenske TS, Shah NN) Oncologist 2019 Nov;24(11):1488-1495 PMID: 31467178 PMCID: PMC6853108 SCOPUS ID: 2-s2.0-85071466837 08/31/2019 9 Citations

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. (Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P) Blood Cancer J 2019 Jul 29;9(8):56 PMID: 31358733 PMCID: PMC6663939 SCOPUS ID: 2-s2.0-85069933026 07/31/2019 19 Citations

Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. (Badar T, Khan MA, Szabo A, Drobyski W, Chhabra S, Dhakal B, Fenske TS, Hamadani M, Hari P, Jerkins JH, Shah NN, Shaw BE, D'Souza A) Amyloid 2019 Dec;26(4):210-215 PMID: 31347424 SCOPUS ID: 2-s2.0-85074118154 07/28/2019 3 Citations

Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. (Dhakal B, Giri S, Levin A, Rein L, Fenske TS, Chhabra S, Shah NN, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani M) JAMA Netw Open 2019 Jul 03;2(7):e196476 PMID: 31276175 PMCID: PMC12124690 SCOPUS ID: 2-s2.0-85068511187 07/06/2019 14 Citations

Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. (Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen AF, Fenske TS) Blood Adv 2019 Jun 11;3(11):1661-1669 PMID: 31167818 PMCID: PMC6560348 SCOPUS ID: 2-s2.0-85067501987 06/07/2019 28 Citations

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. (Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP) Blood Adv 2019 May 28;3(10):1568-1573 PMID: 31101647 PMCID: PMC6538868 SCOPUS ID: 2-s2.0-85067043385 05/19/2019 25 Citations

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. (Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR) Clin Cancer Res 2019 Jul 15;25(14):4264-4270 PMID: 31004001 PMCID: PMC8020996 SCOPUS ID: 2-s2.0-85069054532 04/21/2019 74 Citations

Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. (Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2019 Aug;25(8):1689-1694 PMID: 30965140 SCOPUS ID: 2-s2.0-85065022222 04/10/2019 78 Citations

A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. (D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A) Biol Blood Marrow Transplant 2019 Aug;25(8):1492-1497 PMID: 30959163 SCOPUS ID: 2-s2.0-85065451525 04/09/2019 25 Citations

Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. (Shah NN, Maatman T, Hari P, Johnson B) Front Oncol 2019;9:146 PMID: 30915277 PMCID: PMC6423158 SCOPUS ID: 2-s2.0-85063343499 03/28/2019 142 Citations

Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. (Kanate AS, Szabo A, Raj RV, Bower K, Grulke R, Shah N, Ross KG, Cumpston A, Craig M, Pasquini MC, Shah N, Hari P, Hamadani M, Chhabra S) Biol Blood Marrow Transplant 2019 Jul;25(7):1456-1464 PMID: 30878605 SCOPUS ID: 2-s2.0-85064323899 03/18/2019 20 Citations

Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas. (Levin A, Shah NN) Am J Hematol 2019 May;94(S1):S18-S23 PMID: 30652353 SCOPUS ID: 2-s2.0-85060610905 01/18/2019 22 Citations

Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. (Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M) J Hematol Oncol 2019 Jan 10;12(1):6 PMID: 30630534 PMCID: PMC6329157 SCOPUS ID: 2-s2.0-85059829766 01/12/2019 34 Citations

Clinical Outcomes and Healthcare Resource Utilization for Gastrointestinal Acute Graft-versus-Host Disease after Allogeneic Transplantation for Hematologic Malignancy: A Retrospective US Administrative Claims Database Analysis. (Johnson BH, Taylor A, Kim G, Drahos J, Yang J, Akbari M, Shah NN) Biol Blood Marrow Transplant 2019 Apr;25(4):834-841 PMID: 30625389 SCOPUS ID: 2-s2.0-85061103905 01/10/2019 11 Citations

Allogenic transplant for non-hodgkin lymphoma (Narra RK, Shah NN) Hematopoietic Cell Transplantation for Malignant Conditions 1 January 2019:209-229 SCOPUS ID: 2-s2.0-85082261875 01/01/2019

Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. (Shah NN, Szabo A, Saba R, Strelec L, Kodali D, Vaughn JL, Esan O, Yang DT, Mato AR, Kanate AS, Olteanu H, Hamadani M, Fenske TS, Kenkre VP, Svoboda J, Cashen AF, Epperla N) Clin Lymphoma Myeloma Leuk 2019 Feb;19(2):95-102 PMID: 30581160 SCOPUS ID: 2-s2.0-85058679508 12/26/2018 13 Citations

Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. (Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M) Biol Blood Marrow Transplant 2019 Apr;25(4):827-833 PMID: 30572109 SCOPUS ID: 2-s2.0-85059680507 12/21/2018 29 Citations

Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis. (Bair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, Singavi AN, Reddy N, Khan N, Andreadis C, Vu K, Huntington SF, Giri S, Ujjani C, Howlett C, Faheem M, Youngman MR, Nasta SD, Landsburg DJ, Schuster SJ, Svoboda J) Oncologist 2019 Jul;24(7):955-962 PMID: 30568021 PMCID: PMC6656463 SCOPUS ID: 2-s2.0-85058939991 12/21/2018 31 Citations

Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review. (Fløisand Y, Lazarevic VL, Maertens J, Mattsson J, Shah NN, Zachée P, Taylor A, Akbari M, Quadri S, Parfionovas A, Chen YB) Biol Blood Marrow Transplant 2019 Apr;25(4):720-727 PMID: 30468919 SCOPUS ID: 2-s2.0-85059057830 11/24/2018 52 Citations

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. (Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W) Blood Adv 2018 Nov 13;2(21):2922-2936 PMID: 30396912 PMCID: PMC6234373 SCOPUS ID: 2-s2.0-85064089410 11/07/2018 38 Citations

Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas. (Shah NN, Nagle SJ, Torigian DA, Farwell MD, Hwang WT, Frey N, Nasta SD, Landsburg D, Mato A, June CH, Schuster SJ, Porter DL, Svoboda J) Cytotherapy 2018 Dec;20(12):1415-1418 PMID: 30385043 SCOPUS ID: 2-s2.0-85057563885 11/06/2018 55 Citations

Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS. (Nagle SJ, Shah NN, Ganetsky A, Landsburg DJ, Nasta SD, Mato A, Schuster SJ, Reshef R, Tsai DE, Svoboda J) Int J Hematol Oncol 2017 Dec;6(4):113-121 PMID: 30302232 PMCID: PMC6171986 10/12/2018

Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. (Voshtina E, Szabo A, Hamadani M, Fenske TS, D'Souza A, Chhabra S, Saber W, Drobyski WR, Hari P, Shah NN) Biol Blood Marrow Transplant 2019 Jan;25(1):e33-e38 PMID: 30244105 SCOPUS ID: 2-s2.0-85055445894 09/24/2018 12 Citations

Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. (Sahebi F, Garderet L, Kanate AS, Eikema DJ, Knelange NS, Alvelo OFD, Koc Y, Blaise D, Bashir Q, Moraleda JM, Dreger P, Sanchez JF, Ciurea S, Schouten H, Shah NN, Verbeek M, Rösler W, Diez-Martin JL, Schoenland S, D'Souza A, Kröger N, Hari P) Biol Blood Marrow Transplant 2019 Feb;25(2):335-342 PMID: 30243581 PMCID: PMC6339830 SCOPUS ID: 2-s2.0-85055703569 09/24/2018 21 Citations

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. (Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C) Am J Hematol 2018 Nov;93(11):1394-1401 PMID: 30132965 PMCID: PMC7552812 SCOPUS ID: 2-s2.0-85053839727 08/23/2018 60 Citations

Daratumumab in Primary Effusion Lymphoma. (Shah NN, Singavi AK, Harrington A) N Engl J Med 2018 Aug 16;379(7):689-690 PMID: 30110586 SCOPUS ID: 2-s2.0-85051817119 08/16/2018 35 Citations

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. (Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C) Haematologica 2018 Sep;103(9):1511-1517 PMID: 29880613 PMCID: PMC6119152 SCOPUS ID: 2-s2.0-85052872031 06/09/2018 145 Citations

Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. (Knight JM, Kerswill SA, Hari P, Cole SW, Logan BR, D'Souza A, Shah NN, Horowitz MM, Stolley MR, Sloan EK, Giles KE, Costanzo ES, Hamadani M, Chhabra S, Dhakal B, Rizzo JD) BMC Cancer 2018 May 24;18(1):593 PMID: 29793446 PMCID: PMC5968588 SCOPUS ID: 2-s2.0-85047544800 05/26/2018 31 Citations

Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. (Dhakal B, D'Souza A, Lakshman A, Hamadani M, Chhabra S, Thompson R, Shah N, Pasquini M, Hari P) Biol Blood Marrow Transplant 2018 Aug;24(8):1610-1614 PMID: 29751116 SCOPUS ID: 2-s2.0-85048069667 05/12/2018 9 Citations

Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. (Shah NN, Ahn KW, Litovich C, Fenske TS, Ahmed S, Battiwalla M, Bejanyan N, Dahi PB, Bolaños-Meade J, Chen AI, Ciurea SO, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera AF, Haverkos BM, Holmberg L, Hossain NM, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS, Nishihori T, Rezvani AR, D'Souza A, Savani BN, Ulrickson ML, Waller EK, Sureda A, Smith SM, Hamadani M) Blood Adv 2018 Apr 24;2(8):933-940 PMID: 29685953 PMCID: PMC5916010 SCOPUS ID: 2-s2.0-85055419410 04/25/2018 26 Citations

Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. (Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, Shaw BE, Saber W, Rizzo JD, Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S) Biol Blood Marrow Transplant 2018 Aug;24(8):1664-1670 PMID: 29680516 SCOPUS ID: 2-s2.0-85047194888 04/24/2018 36 Citations

Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. (Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A) Bone Marrow Transplant 2018 Sep;53(9):1210-1213 PMID: 29679076 SCOPUS ID: 2-s2.0-85045751124 04/22/2018 7 Citations

Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. (Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, Bachanova V, Bacher U, Bashey A, Bolaños-Meade J, Cairo M, Chen A, Chhabra S, Copelan E, Dahi PB, Aljurf M, Farooq U, Ganguly S, Hertzberg M, Holmberg L, Inwards D, Kanate AS, Karmali R, Kenkre VP, Kharfan-Dabaja MA, Klein A, Lazarus HM, Mei M, Mussetti A, Nishihori T, Ramakrishnan Geethakumari P, Saad A, Savani BN, Schouten HC, Shah N, Urbano-Ispizua A, Vij R, Vose J, Sureda A, Hamadani M) Cancer 2018 Jun 15;124(12):2541-2551 PMID: 29645093 PMCID: PMC5990449 SCOPUS ID: 2-s2.0-85045242474 04/13/2018 58 Citations

What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani et al. (Shah NN, Fenske TS, Hamadani M, Svoboda J) Br J Haematol 2019 Mar;184(5):838-840 PMID: 29528099 SCOPUS ID: 2-s2.0-85043472454 03/13/2018

Leukemic phase and CSF involvement of diffuse large B-cell lymphoma with a complex karyotype including a TP53 deletion. (Sinkoff J, Olteanu H, Peterson JF, Shah NN) Clin Case Rep 2018 Jan;6(1):235-237 PMID: 29375876 PMCID: PMC5771872 01/30/2018

Graft-versus-host disease-associated hepatic portal venous gas. (Singavi AK, Shah NN) Br J Haematol 2018 Apr;181(1):9 PMID: 29363735 SCOPUS ID: 2-s2.0-85041005174 01/25/2018 2 Citations

Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation. (Bhella S, Majhail NS, Betcher J, Costa LJ, Daly A, Dandoy CE, DeFilipp Z, Doan V, Gulbis A, Hicks L, Juckett M, Khera N, Krishnan A, Selby G, Shah NN, Stricherz M, Viswabandya A, Bredeson C, Seftel MD) Biol Blood Marrow Transplant 2018 May;24(5):909-913 PMID: 29360515 SCOPUS ID: 2-s2.0-85044666234 01/24/2018 39 Citations

Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. (Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M) Haematologica 2018 Apr;103(4):717-727 PMID: 29351985 PMCID: PMC5865423 SCOPUS ID: 2-s2.0-85044420638 01/21/2018 42 Citations

Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. (Zhu F, Shah N, Xu H, Schneider D, Orentas R, Dropulic B, Hari P, Keever-Taylor CA) Cytotherapy 2018 Mar;20(3):394-406 PMID: 29287970 SCOPUS ID: 2-s2.0-85039050230 12/31/2017 94 Citations

R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. (Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J) Br J Haematol 2018 Feb;180(4):534-544 PMID: 29265182 SCOPUS ID: 2-s2.0-85038422379 12/22/2017 89 Citations

Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. (Epperla N, Ahn KW, Armand P, Jaglowski S, Ahmed S, Kenkre VP, Savani B, Jagasia M, Shah NN, Fenske TS, Sureda A, Smith SM, Hamadani M) Biol Blood Marrow Transplant 2018 Jan;24(1):78-85 PMID: 29032272 PMCID: PMC5743624 SCOPUS ID: 2-s2.0-85034849252 10/17/2017 9 Citations

Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. (Thompson J, Yin Z, D'Souza A, Fenske T, Hamadani M, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N, Shaw BE, Shahir K, Banerjee A, Drobyski WR) Biol Blood Marrow Transplant 2017 Nov;23(11):1955-1960 PMID: 28757436 SCOPUS ID: 2-s2.0-85028446880 08/02/2017 25 Citations

Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. (Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN) Am J Hematol 2017 Oct;92(10):E610-E611 PMID: 28699171 SCOPUS ID: 2-s2.0-85026445343 07/13/2017 7 Citations

Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. (Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M) Clin Lymphoma Myeloma Leuk 2017 May;17(5):305-311.e2 PMID: 28284742 SCOPUS ID: 2-s2.0-85015693044 03/13/2017 8 Citations

Extracavitary primary effusion lymphoma associated with hemophagocytic lymphohistiocytosis. (Epperla N, Harrington AM, Hemauer K, Shah NN) Am J Hematol 2016 Nov;91(11):1161-1164 PMID: 27414752 SCOPUS ID: 2-s2.0-84989227504 10/21/2016 8 Citations

Acute promyelocytic leukemia presenting as a paraspinal mass. (Shah NN, Stonecypher M, Gopal P, Luger S, Bagg A, Perl A) J Community Support Oncol 2016 Mar;14(3):126-9 PMID: 27058871 SCOPUS ID: 2-s2.0-84962427364 04/09/2016 9 Citations

Improving the Safety of Oral Chemotherapy at an Academic Medical Center. (Shah NN, Casella E, Capozzi D, McGettigan S, Gangadhar TC, Schuchter L, Myers JS) J Oncol Pract 2016 Jan;12(1):e71-6 PMID: 26733627 PMCID: PMC4960462 SCOPUS ID: 2-s2.0-84958581892 01/07/2016 21 Citations

Implementation of an Advanced Practice Provider Service on an Allogeneic Stem Cell Transplant Unit: Impact on Patient Outcomes. (Shah NN, Kucharczuk CR, Mitra N, Hirsh R, Svoboda J, Porter D, Loren A, Frey N, Schapira MM) Biol Blood Marrow Transplant 2015 Sep;21(9):1692-8 PMID: 26028503 SCOPUS ID: 2-s2.0-84938993007 06/02/2015 4 Citations

The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma. (Nagle SJ, Chong EA, Chekol S, Shah NN, Nasta SD, Glatstein E, Plastaras JP, Torigian DA, Schuster SJ, Svoboda J) Cancer Med 2015 Jan;4(1):7-15 PMID: 25205600 PMCID: PMC4312112 SCOPUS ID: 2-s2.0-85005781388 09/11/2014 19 Citations

Extracavitary primary effusion lymphoma initially presenting with hemophagocytic lymphohistocytosis. (Shah NN, Harrison N, Stonecypher M, Frank D, Amorosa V, Svoboda J) Clin Lymphoma Myeloma Leuk 2014 Oct;14(5):e157-60 PMID: 25027567 SCOPUS ID: 2-s2.0-84908663975 07/17/2014 9 Citations

Plasmacytic post-transplant lymphoproliferative disorder: a case series of nine patients. (Karuturi M, Shah N, Frank D, Fasan O, Reshef R, Ahya VN, Bromberg M, Faust T, Goral S, Schuster SJ, Stadtmauer EA, Tsai DE) Transpl Int 2013 Jun;26(6):616-22 PMID: 23551167 SCOPUS ID: 2-s2.0-84878012301 04/05/2013 35 Citations

Last update: 05/16/2025

© 2025 Clinical & Translational Science Institute
Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53223

Publication and ontology data from NCBI | Disclaimer and Copyright

This site is a collaborative effort of the Medical College of Wisconsin and the Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number 2UL1TR001436) at the National Institutes of Health (NIH).

Faculty Collaboration Database

Profiles for MCW, MU, MSOE, UWM, BCW, CW, Froedtert, and VA Faculty

Nirav N. Shah MD

Professor

Publications (149)